Clinical Trials Logo

Clinical Trial Details — Status: Unknown status

Administrative data

NCT number NCT00743977
Other study ID # URG/STEROP/001
Secondary ID
Status Unknown status
Phase N/A
First received August 28, 2008
Last updated August 28, 2008
Start date August 2008

Study information

Verified date August 2008
Source Universal Enterprises
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The present study aims at comparing the pharmacokinetics of the original formulation of phenazopyridine and a same generic product.


Recruitment information / eligibility

Status Unknown status
Enrollment 24
Est. completion date
Est. primary completion date November 2008
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria:

- Healthy subjects aged 18 to 55 (Male & Female)

- Physically and mentally healthy subjects as confirmed by an interview, medical history, clinical examination, laboratory tests

- Informed consent signed by the subject

- The subject is co-operative and available for the entire study

- Not pregnant or nursing

- Normal renal and hepatic function

Exclusion Criteria:

- Evidence in the subject medical history or in the medical examination of any clinically significant hepatic, renal, gastrointestinal, cardiovascular, pulmonary, hematological or other significant acute or chronic abnormalities which might influence either the safety of the subject or the absorption, distribution, metabolism or excretion of the active agent under investigation

- Hypersensitivity to subject drug, atopic eczema or allergic bronchial asthma

- Evidence of hypertension (blood pressure after 3 minutes sitting>160/95 mm Hg)

- Evidence of chronic or acute infectious diseases;

- History or evidence of malignant tumors;

- Evidence of hyperuricaemia, elevated serum uric acid (>8.0 mg/dl)

- Hepatic or renal impairment; elevated serum creatinine (>1.4 mg/dl)

- Planned vaccination during the time course of the study

- Adherence to a diet (i.e, vegetarian) or life style (incl. extreme sports) that might interfere with the investigation

- Laboratory test results outside the tolerance values as laid down by the study centre, which may be an evidence of disease. Positive result of HIV1/2, HCV antibody or HBs antigen testing

- Regular use of any medication within four weeks prior to commencement of the study (self-medication or prescription)

- Single use of any medication (including OTC) that are not expressively permitted within two weeks prior to start of the study

- Abuse of alcohol, caffeine or tobacco (equivalent to more than 10 cigarettes a day)

- Drug addiction

- Participation in a clinical investigation or blood donation of more than 250 ml within the past eight weeks or blood donation of less than 250 ml within the past 4 week

- Subjects who are known or suspected

- not to comply with the study directives

- not to be reliable or trustworthy

- not to be capable of understanding and evaluating the information given to them as part of the formal information policy (informed consent),in particular regarding the risks and discomfort to which they would agree to be exposed.

- to be in such a precarious financial situation that they no longer weigh up the possible risks of their participation and the unpleasantness they may be involved in.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Phenazopyridine HCl
100mg tablet in fasting state

Locations

Country Name City State
Pakistan Health Care Hospital Karachi

Sponsors (1)

Lead Sponsor Collaborator
Universal Enterprises

Country where clinical trial is conducted

Pakistan, 

Outcome

Type Measure Description Time frame Safety issue
Primary The primary outcome of the study will be to determine the bioequivalence of both the formulations of phenazopyridine regular intervals after drug dosing
See also
  Status Clinical Trial Phase
Completed NCT03093506 - Effects of Micro-dose and Low-dose Recombinant Human Erythropoietin on Mitochondrial Function and Cognitive Performance Early Phase 1
Completed NCT00526968 - The Effects of a Novel NMDA NR2B-Subtype Selective Antagonist, EVT 101, on Brain Function Phase 1
Completed NCT03277456 - A Study to Determine the Safety and Immunogenicity of the Candidate Influenza Vaccine MVA-NP+M1 Early Phase 1
Completed NCT02922933 - A Study to Examine the Effect of Omeprazole, Famotidine, and an Acidic Beverage on the Pharmacokinetics of Entinostat in Healthy Adult Subjects Phase 1
Completed NCT01464385 - Nutrition Beverage Tolerance Study Phase 2
Completed NCT01468714 - A Study To Estimate The Effect Of Ketoconazole On The Pharmacokinetics Of Pf-04937319 In Healthy Subjects Phase 1
Completed NCT01452425 - In Vivo Optical Spectroscopy Monitoring in a New Model of Muscular Compartment Syndrome Phase 1
Completed NCT02922946 - Study to Determine the Effect of the Timing of a Meal on the Pharmacokinetics of Entinostat Phase 1
Completed NCT00254449 - Effect of NGX-4010 on ENFD and Sensory Function Phase 1
Completed NCT01618877 - A Randomized, Double-blind, Pharmacokinetics Study to Assess Safety, Tolerability of Levetiracetam 45 Minutes Intravenous Infusion During 4 Days of Bid Dosing in Chinese Healthy Volunteers Phase 1
Completed NCT01618903 - An Open-label, Bioequivalence Study to Evaluate LEV Administered as a 45-min Intravenous Infusion and Same Dosage LEV Oral Tablet in Chinese Phase 1
Completed NCT00752466 - A Drug Interaction Study of the Pharmacokinetics of Topiramate and FLUNARIZINE When Given Together or Separately Phase 1
Completed NCT00166933 - Minimal Erythema Dose of UV-B in Normal Population of Taiwan N/A
Completed NCT05519514 - Bio-Equivalence Study of Budesonide Prolonged-release Tablets 9 Mg In Healthy Human Adult Subjects Phase 1
Completed NCT01776437 - Study of BMN 673, a PARP Inhibitor, in Healthy Adult Male Volunteers Phase 1
Completed NCT01437033 - Breath Test for Chemicals (Volatile Organic Compounds)
Completed NCT01445860 - Drug-Drug Interaction Study Of Effect Of PF-03882845 On Simvastatin Pharmacokinetics Phase 1
Completed NCT00744809 - TMC278-TiDP6-C152: A Study to Assess the Effects of TMC278 and Efavirenz (EFV) on the QT/QTc Interval (Heart Conduction and Heart Rhythm) in Healthy Volunteers. Phase 1